ARMC6 Inhibitors
ARMC6 inhibitors encompass a range of compounds that indirectly facilitate the degradation or destabilization of the ARMC6 protein through various intracellular pathways. Bortezomib, a proteasome inhibitor, can indirectly lead to the degradation of ARMC6 by causing an accumulation of polyubiquitinated proteins, including potentially misfolded ARMC6, which can trigger cellular responses aimed at degrading these proteins. Similarly, MG-132 prevents the proteasomal degradation of polyubiquitinated proteins, which may include ARMC6. This accumulation could lead to a cellular environment that induces the misfolding and subsequent degradation of ARMC6.
Lenalidomide, thalidomide, and pomalidomide, all of which bind to cereblon, modulate the substrate specificity of E3 ubiquitin ligases. This modulation has the potential to change the ubiquitination pattern of ARMC6, leading to its degradation. On the other hand, autophagy inhibitors like chloroquine, hydroxychloroquine, 3-methyladenine, and spautin-1 can lead to the accumulation of cellular components, including ARMC6. This can induce stress responses within the cell that target ARMC6 for degradation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, potentially including misfolded ARMC6 proteins. The subsequent proteotoxic stress may induce cellular responses that degrade ARMC6. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A reversible proteasome inhibitor that prevents the degradation of polyubiquitinated proteins, which could include ARMC6 if it is marked for proteasomal degradation, leading to its accumulation and potential misfolding and degradation. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
An immunomodulatory drug that modulates the substrate specificity of the E3 ubiquitin ligase cereblon, potentially altering the ubiquitination pattern of ARMC6 and leading to its degradation. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
A cereblon-binding compound that modulates the ubiquitination process. Altered ubiquitination can lead to the degradation of specific proteins, including potentially ARMC6. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
A thalidomide analog that also binds to cereblon, modifying the E3 ligase activity and potentially enhancing the degradation of ARMC6 through ubiquitination. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
An autophagy inhibitor that can prevent the lysosomal degradation of cellular components, which could lead to the accumulation of ARMC6, inducing stress responses that target ARMC6 for degradation. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Similar to chloroquine, it is an autophagy inhibitor that may disrupt the normal turnover of cellular components including ARMC6, potentially leading to cellular stress and ARMC6 degradation. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
An inhibitor of class III PI3K, known to interfere with autophagy initiation. This could prevent the autophagic degradation of ARMC6, leading to its accumulation and potential degradation. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
An autophagy inhibitor that promotes the degradation of the autophagy-related protein Beclin-1, which could disrupt the autophagic turnover of ARMC6, resulting in its degradation. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $113.00 $1035.00 | 7 | |
A Src kinase inhibitor that may disrupt downstream signaling pathways involved in the regulation of ARMC6 stability and localization, potentially leading to ARMC6 degradation. | ||||||